LeserbriefKommentar
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
JAMA · 2024
DOI: 10.1001/jama.2024.15488 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Caichen Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AspirinBreast NeoplasmsFemaleHumansAnti-Inflammatory Agents, Non-SteroidalChemotherapy, AdjuvantClinical Trials, Phase III as TopicDisease-Free SurvivalMulticenter Studies as TopicNeoplasm InvasivenessNeoplasm Recurrence, LocalPlacebosRandomized Controlled Trials as Topic
Substanzen
Anti-Inflammatory Agents, Non-SteroidalAspirinPlacebos
Autor:innen und Institutionen
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Li, C., He, J., & Liang, W. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. https://doi.org/10.1001/jama.2024.15488
Vancouver
Li C, He J, Liang W. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 2024. doi:10.1001/jama.2024.15488
BibTeX
@article{Li2024,
author = {Li, Caichen and He, Jianxing and Liang, Wenhua},
title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.15488}
}
EUVIMED